Vanrafia
Payments companies reported to CMS as associated with Vanrafia. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vanrafia, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vanrafia
These are the largest totals companies reported as associated with Vanrafia. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Graham Walker | Stanford, CA | Emergency Medicine | $70,500.00 |
| Joseph Habboushe | New York, NY | Emergency Medicine | $70,500.00 |
| Nissreen Elfadawy | Chardon, OH | Nephrology (Internal Medicine) | $9,436.22 |
| Arvind Madan | Orlando, FL | Nephrology (Internal Medicine) | $9,244.53 |
| Joel Topf | Roseville, MI | Nephrology (Internal Medicine) | $8,090.79 |
| Arun Rajasekaran | Albuquerque, NM | Nephrology (Internal Medicine) | $7,402.30 |
| Anjay Rastogi | Los Angeles, CA | Nephrology (Internal Medicine) | $6,941.35 |
| Corey Cavanaugh | Cleveland, OH | Nephrology (Internal Medicine) | $6,419.38 |
| Dmitri Vasin | Bremerton, WA | Nephrology (Internal Medicine) | $5,806.97 |
| Nam Vo | Asheville, NC | Nephrology (Internal Medicine) | $5,495.87 |
Prescribed Vanrafia?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.